$LTES
Leet Technology Inc Stock $ltes

$ltes Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000168316824003645 Filed on May 20, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$347.7K	$196.7K	$138.0K
YoY Change	262.62%	299.21%	283.41%
Cost Of Revenue	$158.5K	$157.0K	$186.1K
YoY Change	1.11%	8.2%	-45.33%
Gross Profit	$189.1K	$39.67K	-$48.12K
YoY Change	-410.36%	-141.4%	-84.19%
Gross Profit Margin	54.4%	20.17%	-34.87%
Selling, General & Admin	$78.21K	$168.5K	$346.0K
YoY Change	-71.83%	-55.11%	-10.1%
% of Gross Profit	41.36%	424.71%
Research & Development	$8.972K	$8.960K	-$53.26K
YoY Change	0.17%	-0.23%	-682.08%
% of Gross Profit	4.74%	22.59%
Depreciation & Amortization	$2.610K	$2.610K	$28.24K
YoY Change	-3.69%	-13.23%	-121.79%
% of Gross Profit	1.38%	6.58%
Operating Expenses	$87.18K	$177.4K	$292.7K
YoY Change	-69.58%	-53.83%	-25.7%
Operating Profit	$101.9K	-$137.8K	-$340.8K
YoY Change	-129.33%	-71.31%	-51.2%
Interest Expense	$3.760K	$0.00	$47.83K
YoY Change	171.28%	-100.0%	-83.91%
% of Operating Profit	3.69%
Other Income/Expense, Net	$111.5K	$14.69K	$38.58K
YoY Change	204.04%	-147.88%	56.7%
Pretax Income	$213.4K	-$123.1K	-$254.4K
YoY Change	-168.65%	-75.91%	-34.21%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$214.2K	-$120.3K	-$253.7K
YoY Change	-168.96%	-76.26%	-33.74%
Net Earnings / Revenue	61.61%	-61.19%	-183.87%
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	151.1M shares	151.1M shares	151.1M shares
Diluted Shares Outstanding	151.1M shares	151.1M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.45K	$18.85K	$16.58K
YoY Change	-75.33%	-72.24%	-54.96%
Cash & Equivalents	$15.45K	$18.85K	$16.58K
Short-Term Investments
Other Short-Term Assets	$34.43K	$29.42K	$15.04K
YoY Change	165.87%	34.83%	28.44%
Inventory
Prepaid Expenses
Receivables	$31.24K	$67.84K	$16.78K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$229.9K	$116.1K	$48.40K
YoY Change	121.6%	-2.35%	-76.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$76.52K	$79.02K	$83.93K
YoY Change	-32.28%	-35.43%	-32.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$76.52K	$79.02K	$83.93K
YoY Change	-33.88%	-38.44%	-36.66%
TOTAL ASSETS
Total Short-Term Assets	$229.9K	$116.1K	$48.40K
Total Long-Term Assets	$76.52K	$79.02K	$83.93K
Total Assets	$306.4K	$195.1K	$132.3K
YoY Change	39.61%	-21.08%	-60.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$58.22K	$57.39K	$60.38K
YoY Change	-88.07%	-88.83%	-88.61%
Accrued Expenses	$623.1K	$675.3K	$736.2K
YoY Change	112.0%	63.38%	93.81%
Deferred Revenue	$13.95K	$210.1K	$313.6K
YoY Change	-95.11%	-12.58%	15.81%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.046M	$4.166M	$4.056M
YoY Change	14.4%	26.76%	41.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.046M	$4.166M	$4.056M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.046M	$4.166M	$4.056M
YoY Change	14.4%	26.76%	41.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.43M	-$12.55M	-$12.33M
YoY Change	7.29%	12.25%	16.6%
Common Stock	$15.11K	$15.11K	$15.11K
YoY Change	0.0%	-0.53%	-1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.580M	-$9.717M	-$9.578M
YoY Change
Total Liabilities & Shareholders Equity	$306.4K	$195.1K	$132.3K
YoY Change	39.61%	-21.08%	-60.8%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$214.2K	-$120.3K	-$253.7K
YoY Change	-168.96%	-76.26%	-33.74%
Depreciation, Depletion And Amortization	$2.610K	$2.610K	$28.24K
YoY Change	-3.69%	-13.23%	-121.79%
Cash From Operating Activities	-$151.5K	-$330.2K	-$286.0K
YoY Change	-54.2%	-16.26%	-55.22%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$20.00
YoY Change	-100.0%	-100.0%	-84.62%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	$0.00	$0.00	$20.00
YoY Change	-100.0%	-100.0%	-99.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	122.6K	$347.5K	343.7K
YoY Change	-66.88%	-20.4%	-39.42%
NET CHANGE
Cash From Operating Activities	-151.5K	-$330.2K	-286.0K
Cash From Investing Activities	0.000	$0.00	20.00
Cash From Financing Activities	122.6K	$347.5K	343.7K
Net Change In Cash	-28.97K	$2.267K	57.70K
YoY Change	-173.79%	-92.71%	-64.67%
FREE CASH FLOW
Cash From Operating Activities	-$151.5K	-$330.2K	-$286.0K
Capital Expenditures	$0.00	$0.00	-$20.00
Free Cash Flow	-$151.5K	-$330.2K	-$286.0K
YoY Change	-54.19%	-16.69%	-55.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	7783 1636
CY2024Q1	dei	Security12g Title Security12gTitle	Common Stock Par value, $0.0001
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	151096262	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16580	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67844	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16781	usd
CY2024Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	29420	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	15036	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	116111	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	48397	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79019	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83932	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	79019	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	83932	usd
CY2024Q1	us-gaap	Assets Assets	195130	usd
CY2023Q4	us-gaap	Assets Assets	132329	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	57387	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	60378	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	675261	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	736212	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	307792	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	316471	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	210082	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	313616	usd
CY2024Q1	LTES	Due To Related Party Current DueToRelatedPartyCurrent	2915653	usd
CY2023Q4	LTES	Due To Related Party Current DueToRelatedPartyCurrent	2629435	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4166175	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4056112	usd
CY2024Q1	us-gaap	Liabilities Liabilities	4166175	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4056112	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5662325	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151096262	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151096262	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151096262	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151096262	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	15110	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2773081	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32074	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12334229	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9578012	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-8096	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9586108	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132329	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	156986	usd
CY2024Q1	LTES	Research And Development Expense Reversal ResearchAndDevelopmentExpenseReversal	-8959	usd
CY2023Q1	LTES	Research And Development Expense Reversal ResearchAndDevelopmentExpenseReversal	-8981	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	168471	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	375330	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	177430	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	384311	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-137763	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-480136	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	-0	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	4160	usd
CY2024Q1	LTES	Recovery Written Off Of Accounts Receivable RecoveryWrittenOffOfAccountsReceivable	0	usd
CY2023Q1	LTES	Recovery Written Off Of Accounts Receivable RecoveryWrittenOffOfAccountsReceivable	-33286	usd
CY2024Q1	LTES	Foreign Exchange Gain Currency Transaction Gain Loss Before Tax ForeignExchangeGainCurrencyTransactionGainLossBeforeTax	489	usd
CY2023Q1	LTES	Foreign Exchange Gain Currency Transaction Gain Loss Before Tax ForeignExchangeGainCurrencyTransactionGainLossBeforeTax	5916	usd
CY2024Q1	LTES	Cybersecurity Service Income CybersecurityServiceIncome	14204	usd
CY2023Q1	LTES	Cybersecurity Service Income CybersecurityServiceIncome	480	usd
CY2024Q1	LTES	Sundry Income Expense Net SundryIncomeExpenseNet	0	usd
CY2023Q1	LTES	Sundry Income Expense Net SundryIncomeExpenseNet	365	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14693	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30685	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-123070	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-510821	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-123070	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-510821	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2743	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4028	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-120327	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-506793	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	75808	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5956	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47262	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-516777	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	151096262	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151096262	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152386802	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152386802	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7807372	usd
CY2023Q1	us-gaap	Dividends Dividends	94372	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5956	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-510821	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8418521	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9586108	usd
CY2024Q1	us-gaap	Dividends Dividends	94372	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	75808	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-123070	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9727742	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-123070	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2612	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3008	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1894	usd
CY2024Q1	LTES	Amortization Noncash Financing Cost AmortizationNoncashFinancingCost	0	usd
CY2023Q1	LTES	Amortization Noncash Financing Cost AmortizationNoncashFinancingCost	2266	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	33286	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3081	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53717	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-94020	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	14809	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	10170	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1382	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-15561	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-44791	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	31529	usd
CY2024Q1	LTES	Increase Decrease In Accrued Compensation Payable To Officers And Directors IncreaseDecreaseInAccruedCompensationPayableToOfficersAndDirectors	0	usd
CY2023Q1	LTES	Increase Decrease In Accrued Compensation Payable To Officers And Directors IncreaseDecreaseInAccruedCompensationPayableToOfficersAndDirectors	6669	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-95011	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-30419	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3081	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-330168	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-394299	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2029	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2029	usd
CY2024Q1	LTES	Proceeds From Repayments Of Director ProceedsFromRepaymentsOfDirector	3179	usd
CY2023Q1	LTES	Proceeds From Repayments Of Director ProceedsFromRepaymentsOfDirector	0	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	344336	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	436553	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	347515	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	436553	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-15080	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9133	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2267	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31092	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16580	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36808	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18847	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67900	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18847	usd
CY2024Q1	LTES	Working Capital Deficit WorkingCapitalDeficit	-4050064	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12548928	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-123070	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zOInBuc0FP84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zIAet3v3JU3j">Use of estimates and assumptions</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements during the period reported. Actual results may differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	7000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151096262	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151096262	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151096262	shares
CY2024Q1	us-gaap	Revenues Revenues	196653	usd
CY2023Q1	us-gaap	Revenues Revenues	49260	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151096262	shares
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	159804	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	164311	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80785	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80379	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79019	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83932	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2612	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3008	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-120327	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-506793	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	151096262	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151096262	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152386802	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152386802	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	LTES	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	2915653	usd
CY2023Q4	LTES	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	2629435	usd
CY2024Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	3179	usd
CY2023Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	29722	usd
CY2023Q4	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	3152	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-003645-index-headers.html	Edgar Link	pending
0001683168-24-003645-index.html	Edgar Link	pending
0001683168-24-003645.txt	Edgar Link	pending
0001683168-24-003645-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
leet_ex3101.htm	Edgar Link	pending
leet_ex3102.htm	Edgar Link	pending
leet_ex3201.htm	Edgar Link	pending
leet_ex3202.htm	Edgar Link	pending
leet_i10q-033124.htm	Edgar Link	pending
ltes-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
ltes-20240331_def.xml	Edgar Link	unprocessable
ltes-20240331_lab.xml	Edgar Link	unprocessable
ltes-20240331_pre.xml	Edgar Link	unprocessable
leet_i10q-033124_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ltes-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LTES
Leet Technology Inc Stock $ltes

2024 Q2 Form 10-Q Financial Statement

#000168316824003645 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LTES Leet Technology Inc Stock $ltes

2024 Q2 Form 10-Q Financial Statement

#000168316824003645 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LTES
Leet Technology Inc Stock $ltes